{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:47:17Z","timestamp":1778953637432,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Only a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>By means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy. We excluded patients with only BRAF, NRAS, or CKIT alterations and patients who received molecularly matched therapy for less than 15 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 26 patients with a median follow-up of 8 months (1-54), a median age of 63 years (24-89), and a sex ratio of 2.7. These patients had been heavily pretreated, and 64% had elevated LDH levels. The disease control rate was 38%, with 4 cases of partial response (overall response rate: 15%) and 6 of stable disease for at least 6 months. The median duration of treatment was 3.1 months (0.9-13.5). Among patients with disease control, the median duration of control was 6.6 months (2.6-13.5) and 3 cases were ongoing at the end of the study. Patients with controlled disease had GNA11, MAP2K1, FYCO1-RAF1, HRAS, ATM, CCND1, MDM2\/CDK4, and CDKN2A\/NRAS alterations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High-throughput sequencing followed by matched targeted therapy is a promising approach for patients with advanced melanoma refractory to approved treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae085","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T17:26:06Z","timestamp":1716053166000},"page":"e1180-e1188","source":"Crossref","is-referenced-by-count":1,"title":["Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma"],"prefix":"10.1093","volume":"29","author":[{"given":"Emily","family":"Connell","sequence":"first","affiliation":[{"name":"Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258 Dermatology and Skin Cancer Department, , Marseille , France"},{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9milie","family":"Gerard","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux Dermatology Department, , Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Oules","sequence":"additional","affiliation":[{"name":"Cochin Hospital Dermatology Department, , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-2913","authenticated-orcid":false,"given":"Florence","family":"Brunet-Possenti","sequence":"additional","affiliation":[{"name":"Bichat Claude-Bernard Hospital Dermatology Department, , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouck","family":"Lamoureux","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute Dermatology Department, , Montpellier , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Bonnefille","sequence":"additional","affiliation":[{"name":"CHU de N\u00eemes Dermatology Department, , N\u00eemes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorilla","family":"Mary-Prey","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux Dermatology Department, , Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Carrasquilla","sequence":"additional","affiliation":[{"name":"Leon B\u00e9rard Cancer Center Dermatology Department, , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Mouret","sequence":"additional","affiliation":[{"name":"CHU Grenoble Alpes, University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences Dermatology Department, , Grenoble , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[{"name":"Cochin Hospital Dermatology Department, , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Lesage","sequence":"additional","affiliation":[{"name":"CHU de Montpellier Dermatology Department, , Montpellier , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Emmanuel","family":"Stoebner","sequence":"additional","affiliation":[{"name":"CHU de N\u00eemes Dermatology Department, , N\u00eemes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Bartoli","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, CERIMED Radiology Department, , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Monestier","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258 Dermatology and Skin Cancer Department, , Marseille , France"},{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Correard","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Pharmacy Department, , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Gros","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux Tumor Biology and Tumor Bank Department, , Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jeanson","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"},{"name":"Aix Marseille University, CNRS, INSERM, CRCM, APHM Multidisciplinary Oncology and Therapeutic Innovations Department, , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u2019Houcine","family":"Ouafik","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, CNRS, INP, Inst Neurophysiopathol Oncobiology Department, , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258 Dermatology and Skin Cancer Department, , Marseille , France"},{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"},{"name":"Aix Marseille University, CNRS, INSERM, CRCM, APHM Multidisciplinary Oncology and Therapeutic Innovations Department, , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[{"name":"CHU Grenoble Alpes, University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences Dermatology Department, , Grenoble , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Amini-Adle","sequence":"additional","affiliation":[{"name":"Leon B\u00e9rard Cancer Center Dermatology Department, , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-9658","authenticated-orcid":false,"given":"Nausicaa","family":"Malissen","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258 Dermatology and Skin Cancer Department, , Marseille , France"},{"name":"Aix Marseille University, APHM Department of Early Phase Cancer Trial Center (CEPCM) \u201cCLIP2,\u201d , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"85","key":"2024090704212780400_CIT0001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"7","key":"2024090704212780400_CIT0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"2024090704212780400_CIT0003","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2024090704212780400_CIT0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"8","key":"2024090704212780400_CIT0005","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"2024090704212780400_CIT0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11523-020-00764-4","article-title":"A melanoma-tailored next-generation sequencing panel coupled with a comprehensive analysis to improve routine melanoma genotyping","volume":"15","author":"Louveau","year":"2020","journal-title":"Target Oncol"},{"issue":"8","key":"2024090704212780400_CIT0007","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3390\/cancers12082228","article-title":"Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA","volume":"12","author":"Diefenbach","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024090704212780400_CIT0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2024090704212780400_CIT0009","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41598-017-00606-w","article-title":"Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel","volume":"7","author":"de Unamuno Bustos","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"2024090704212780400_CIT0010","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024090704212780400_CIT0011","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1535-7163.MCT-19-0457","article-title":"Clinical application of next-generation sequencing-based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies","volume":"19","author":"Park","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2024090704212780400_CIT0012","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024090704212780400_CIT0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2024090704212780400_CIT0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2022.02.008","article-title":"MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: a multi-centre, retrospective study","volume":"166","author":"Salzmann","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024090704212780400_CIT0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annonc.2020.10.602","article-title":"Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade","volume":"32","author":"Khaddour","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"2024090704212780400_CIT0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.annonc.2020.11.006","article-title":"Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report","volume":"32","author":"Lau","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"2024090704212780400_CIT0017","doi-asserted-by":"crossref","first-page":"a006129","DOI":"10.1101\/mcs.a006129","article-title":"Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency","volume":"7","author":"Khaddour","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"14","key":"2024090704212780400_CIT0018","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","article-title":"Phase Ib\/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma","volume":"28","author":"Schuler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024090704212780400_CIT0019","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","article-title":"Allele-specific mechanisms of activation of MEK1 mutants determine their properties","volume":"8","author":"Gao","year":"2018","journal-title":"Cancer Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/e1180\/59036753\/oyae085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/e1180\/59036753\/oyae085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:07:27Z","timestamp":1725685647000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/9\/e1180\/7676392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,18]]},"published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae085","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,18]]}}}